Citations

Clear

3314 citation(s) found for "Do, Alexander".

The failed adult traumatic brachial plexus reconstruction
Lee, Ellen Y. , Spinner, Robert J. , Shin, Alexander Y. , Shin, Alexander Y , Pulos, Nicholas , Bishop, Allen T.

Mayo Clinic

Journal of Hand Surgery (European Volume) | February 19, 2024 | Volume: 49 | Issue: 11 | Pages: 1298-1312

10.1177/17531934241231170 | PMID 38373612 Get It

Traumatic adult brachial plexus injuries typically cause immediate loss of upper limb function. Timely multidisciplinary treatment in specialized centres often results in a useful helper arm. Both the patient and the surgical team can benefit from an open discussion to set realistic expectations. Surgical reconstruction is customized for each patient, considering their injury factors and functional objectives. Optimizing pain control, adherence to procedure indications and using meticulous surgical techniques help minimize the risk of failing to meet the patient’s goals. The need for potential alternative treatment(s) if the desired result is not achieved should be detailed before the initial reconstruction. This review discusses late treatment options, including tendon transfers, joint fusions, free functioning muscle transfers and prosthetics, for managing the failed primary reconstruction of the traumatic adult brachial plexus.
Abdominal Body Composition Reference Ranges and Association With Chronic Conditions in an Age- and Sex-Stratified Representative Sample of a Geographically Defined American Population
Weston, Alexander D. , Kline, Timothy L. , Rocca, Walter A. , Rocca, Walter A , Weston, Alexander D , Grossardt, Brandon R. , Garner, Hillary W. , Chamberlain, Alanna M. , Allen, Alina M. , Erickson, Bradley J. , Rule, Andrew D. , Sauver, Jennifer L. St.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 19, 2024 | Volume: 79 | Issue: 4 | Pages: No page available

10.1093/gerona/glae055 | PMID 38373180 Get It

Abstract Background Body composition can be accurately quantified from abdominal computed tomography (CT) exams and is a predictor for the development of aging-related conditions and for mortality. However, reference ranges for CT-derived body composition measures of obesity, sarcopenia, and bone loss have yet to be defined in the general population. Methods We identified a population-representative sample of 4 900 persons aged 20 to 89 years who underwent an abdominal CT exam from 2010 to 2020. The sample was constructed using propensity score matching an age and sex stratified sample of persons residing in the 27-county region of Southern Minnesota and Western Wisconsin. The matching included race, ethnicity, education level, region of residence, and the presence of 20 chronic conditions. We used a validated deep learning based algorithm to calculate subcutaneous adipose tissue area, visceral adipose tissue area, skeletal muscle area, skeletal muscle density, vertebral bone area, and vertebral bone density from a CT abdominal section. Results We report CT-based body composition reference ranges on 4 649 persons representative of our geographic region. Older age was associated with a decrease in skeletal muscle area and density, and an increase in visceral adiposity. All chronic conditions were associated with a statistically significant difference in at least one body composition biomarker. The presence of a chronic condition was generally associated with greater subcutaneous and visceral adiposity, and lower muscle density and vertebrae bone density. Conclusions We report reference ranges for CT-based body composition biomarkers in a population-representative cohort of 4 649 persons by age, sex, body mass index, and chronic conditions.
Global trends and outcomes of nerve transfers for treatment of adult brachial plexus injuries
Crowe, Christopher S. , Spinner, Robert J. , Shin, Alexander Y. , Shin, Alexander Y

Mayo Clinic

Journal of Hand Surgery (European Volume) | February 19, 2024 | Volume: 49 | Issue: 9 | Pages: 1147-1156

10.1177/17531934241232062 | PMID 38372245 Get It

The presentation, management and outcomes of brachial plexus injuries are likely to be subject to regional differences across the globe. A comprehensive literature search was performed to identify relevant articles related to spinal accessory to suprascapular, intercostal to musculocutaneous, and ulnar and/or median nerve fascicle to biceps and/or brachialis motor branch nerve transfers for treatment of brachial plexus injuries. A total of 6007 individual brachial plexus injuries were described with a mean follow-up of 38 months. The specific indication for accessory to suprascapular and intercostal to musculocutaneous transfers were considerably different among regions (e.g. upper plexus vs. pan-plexal), while uniform for fascicular transfer for elbow flexion (e.g. upper plexus +/− C7). Similarly, functional recovery was highly variable for accessory to suprascapular and intercostal to musculocutaneous transfers, while British Medical Research Council grade ≥3 strength after fascicular transfer for elbow flexion was frequently obtained. Overall, differences in outcomes seem to be inherent to the specific transfer being utilized. Level of evidence: III
Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study
Pham, Rachel, Zacharias, Niki M. , Ionescu, Filip , Paravathaneni, Mahati, Marchetti, Kathryn , Sanchez, Darren , Mustasam, Arfa, Sandstrom, Reagan, Vikram, Raghu , Schneider, Amy, Pagliaro, Lance C. , Alifrangis, Constantine , Master, Viraj A. , Hernandez, Cindy, Moses, Kelvin A. , Protzel, Chris, Montgomery, Jeffrey S., Ángel, Martín , Tobias‐Machado, Marcos , Pettaway, Curtis A. , Chahoud, Jad , Nazha, Bassel , Chahoud, Jad , Rose, Kyle , Dhillon, Jasreman , Rao, Priya , Albersen, Maarten , Roussel, Eduard , Nazha, Bassel , Spiess, Philippe E.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | February 17, 2024 | Volume: 116 | Issue: 6 | Pages: 966-973

10.1093/jnci/djae034 | PMID 38366627 Get It

Abstract Introduction This study investigated the efficacy and safety of neoadjuvant chemotherapy for locally advance penile squamous cell carcinoma for which current evidence is lacking. Methods Included patients had locally advanced penile squamous cell carcinoma with clinical lymph node metastasis treated with at least 1 dose of neoadjuvant chemotherapy prior to planned consolidative lymphadenectomy. Objective response rates were assessed using Response Evaluation Criteria in Solid Tumors v1.1. The primary and secondary outcomes were overall survival and progression-free survival, estimated by the Kaplan–Meier method. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events v5.0. Results A total of 209 patients received neoadjuvant chemotherapy for locally advanced and clinically node-positive penile squamous cell carcinoma. The study population consisted of 7% of patients with stage II disease, 48% with stage III, and 45% with stage IV. Grade 2 treatment-related adverse events occurred in 35 (17%) patients, and no treatment-related mortality was observed. Of the patients, 201 (97%) completed planned consolidative lymphadenectomy. During follow-up, 106 (52.7%) patients expired, with a median overall survival of 37.0 months (95% confidence interval [CI] = 23.8 to 50.1 months) and median progression-free survival of 26.0 months (95% CI = 11.7 to 40.2 months). Objective response rate was 57.2%, with 87 (43.2%) having partial response and 28 (13.9%) having a complete response. Patients with objective response to neoadjuvant chemotherapy had a longer median overall survival (73.0 vs 17.0 months, P < .01) compared with those who did not. The lymph node pathologic complete response rate was 24.8% in the cohort. Conclusion Neoadjuvant chemotherapy with lymphadenectomy for locally advanced penile squamous cell carcinoma is well tolerated and active to reduce the disease burden and improve long-term survival outcomes.
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Kleinstern, Geffen , Boddicker, Nicholas , O’Brien, Daniel R. , Allmer, Cristine, Rabe, Kari G. , Waller, Rosalie G. , Yan, Huihuang , Ma, Tao , Call, Timothy G. , Bruins, Laura A., Brown, Sochilt , Campos, Cecília Bonolo de , Hanson, Curtis A. , Leis, José F., Ding, Wei , Vachon, Celine M. , Oakes, Christopher C. , Parker, Alexander S. , Brander, Danielle M. , Weinberg, J. Brice , Furman, Richard R. , Shanafelt, Tait D. , Griffin, R. L. , Boddicker, Nicholas J , Waller, Rosalie G , Bruins, Laura, Bonolo de Campos, Cecilia, Vachon, Celine M. , Kay, Neil E , Cerhan, James R , Parikh, Sameer A , Braggio, Esteban , Slager, Susan L , Chaffee, Kari G. , Ding, Wei , Shanafelt, Tait D , Griffin, Rosalie , Norman, Aaron D. , Kay, Neil E. , Cerhan, James R. , Parikh, Sameer A. , Braggio, Esteban , Slager, Susan L.

Mayo Clinic

Blood Advances | February 15, 2024 | Volume: 8 | Issue: 9 | Pages: 2118-2129

10.1182/bloodadvances.2023012242 | PMID 38359367 Get It

Abstract High-count monoclonal B-cell lymphocytosis (HCMBL) is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL, the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-first therapy (TTFT). Little is known about the prognostic impact of somatically mutated genes among individuals with HCMBL. We sequenced DNA from 371 individuals with HCMBL using a targeted sequencing panel of 59 recurrently mutated genes in CLL to identify high-impact mutations. We compared the sequencing results with that of our treatment-naïve CLL cohort (N = 855) and used Cox regression to estimate hazard ratios and 95% confidence intervals (CIs) for associations with TTFT. The frequencies of any mutated genes were lower in HCMBL (52%) than CLL (70%). At 10 years, 37% of individuals with HCMBL with any mutated gene had progressed requiring treatment compared with 10% among individuals with HCMBL with no mutations; this led to 5.4-fold shorter TTFT (95% CI, 2.6-11.0) among HCMBL with any mutated gene vs none, independent of CLL-IPI. When considering individuals with low risk of progression according to CLL-IPI, those with HCMBL with any mutations had 4.3-fold shorter TTFT (95% CI, 1.6-11.8) vs those with none. Finally, when considering both CLL-IPI and any mutated gene status, we observed individuals with HCMBL who were high risk for both prognostic factors had worse prognosis than patients with low-risk CLL (ie, 5-year progression rate of 32% vs 21%, respectively). Among HCMBL, the frequency of somatically mutated genes at diagnosis is lower than that of CLL. Accounting for both the number of mutated genes and CLL-IPI can identify individuals with HCMBL with more aggressive clinical course.
Quality of life following surgery for head and neck cancer: Evidence from ACRIN 6685
Hollenbeak, Christopher S. , Duan, Fenghai , Subramaniam, Rathan M. , Taurone, Alexander, Sicks, JoRean D., Lowe, Val J. , Stack, Brendan C.

Mayo Clinic

Head & Neck | February 14, 2024 | Volume: 46 | Issue: 8 | Pages: 1988-1998

10.1002/hed.27673 | PMID 38353324 Get It

AbstractBackgroundThis study examined the trajectory of health‐related quality of life (HRQoL) for patients with clinical stage N0 HNSCC enrolled in ACRIN 6685 who underwent elective neck dissection(s).MethodsHRQoL of 230 patients in the ACRIN 6685 trial was measured prospectively up to 2 years following surgery using the University of Washington Quality of Life instrument.ResultsGeneral Health Within the Last 7 Days did not differ significantly from baseline at any follow‐up. General Health Relative to Before Cancer fell significantly by 5.8 points following surgery (p = 0.048), and then returned to 3.0 points above baseline at 1 year (p = 0.65). For Overall Quality of Life, HRQoL fell significantly by 4.3 points following surgery (p = 0.031) and then returned to levels not significantly different from baseline.ConclusionsPatients with stage N0 HNSCC experience significant declines in HRQoL immediately following surgery, including neck dissection, which recovers to near or better than baseline within 1–2 years.
Eosinophils restrain humoral alloimmunity after lung transplantation
Mei, Zhongcheng , Khalil, May A. , Guo, Yizhan , Li, Dongge , Banerjee, Anirban , Terada, Yuriko , Yokoyama, Yuhei , Kratzmeier, Christina , Chen, Kelly , Lau, Christine L. , Courneya, Jean-Paul , Luzina, Irina G., Atamas, Sergei P. , Kreisel, Daniel , Jacobsen, Elizabeth A. , Krupnick, Alexander S. , Jacobsen, Elizabeth A , Li, Lushen , Gelman, Andrew E

Mayo Clinic

JCI Insight | February 14, 2024 | Volume: 9 | Issue: 3 | Pages: No page available

10.1172/jci.insight.168911 | PMID 38329123 Get It

While the function of many leukocytes in transplant biology has been well defined, the role of eosinophils is controversial and remains poorly explored. Conflicting data exist regarding eosinophils’ role in alloimmunity. Due to their prevalence in the lung, and their defined role in other pulmonary pathologies such as asthma, we set out to explore the role of eosinophils in the long-term maintenance of the lung allograft. We noted that depletion of eosinophils results in the generation of donor-specific antibodies. Eosinophil depletion increased memory B cell, plasma cell, and antibody-secreting cell differentiation and resulted in de novo generation of follicular germinal centers. Germinal center formation depended on the expansion of CD4 + Foxp3 – Bcl6 + CXCR5 + PD-1 + T follicular helper (Tfh) cells, which increase in number after eosinophil depletion. Mechanistically, we demonstrate that eosinophils prevent Tfh cell generation by acting as the dominant source of IFN-γ in an established lung allograft, thus facilitating Th1 rather than Tfh polarization of naive CD4 + T cells. Our data thus describe what we believe is a unique and previously unknown role for eosinophils in maintaining allograft tolerance and suggest that indiscriminate administration of eosinophil-lytic corticosteroids for treatment of acute cellular rejection may inadvertently promote humoral alloimmunity.
Clinicopathological and cellular senescence biomarkers in chronic stalled wounds
Yu, Grace , Gómez, P. , Lehman, Julia S. , Kirkland, James L. , Meves, Alexander , Wyles, Saranya P. , Yu, Grace T, Gomez, Paul T, Prata, Larissa G, Meves, Alexander , Lehman, Julia S , Yu, Grace T , Prata, Larissa , Tchkonia, Tamar

Mayo Clinic

International Journal of Dermatology | February 14, 2024 | Volume: 63 | Issue: 9 | Pages: 1227-1235

10.1111/ijd.17072 | PMID 38351588 Get It

AbstractBackgroundChronic wounds have been associated with an elevated burden of cellular senescence, a state of essentially irreversible cell cycle arrest, resistance to apoptosis, and a secretory phenotype. However, whether senescent cells contribute to wound chronicity in humans remains unclear. The objective of this article is to assess the role of clinicopathological characteristics and cellular senescence in the time‐to‐healing of chronic wounds.MethodsA cohort of 79 patients with chronic wounds was evaluated in a single‐center academic practice from February 1, 2005, to February 28, 2015, and followed for up to 36 months. Clinical characteristics and wound biopsies were obtained at baseline, and time‐to‐healing was assessed. Wound biopsies were analyzed histologically for pathological characteristics and molecularly for markers of cellular senescence. In addition, biopsy slides were stained for p16INK4a expression.ResultsNo clinical or pathological characteristics were found to have significant associations with time‐to‐healing. A Cox proportional hazard ratio model revealed increased CDKN1A (p21CIP1/WAF1) expression to predict longer time‐to‐healing, and a model adjusted for gender and epidermal hyperplasia revealed increased CDKN1A expression and decreased PAPPA expression to predict longer time‐to‐healing. Increased p16INK4a staining was observed in diabetic wounds compared to non‐diabetic wounds, and the same association was observed in the context of high dermal fibrosis.ConclusionsThe findings of this pilot study suggest that senescent cells contribute to wound chronicity in humans, especially in diabetic wounds.
Implementation of a Liver Transplant-Specific TEE Guide to Expand TEE Utilization and Improve Workflow During Orthotopic Liver Transplantation
Stoker, Alexander D., Khurmi, Narjeet , Girardo, Marlene , Frasco, Peter E.

Mayo Clinic

Journal of Medical Education and Curricular Development | February 12, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23821205241228992 | PMID 38348214 Get It

OBJECTIVES Transesophageal echocardiography (TEE) is being increasingly utilized during orthotopic liver transplantation to guide perioperative management. Obstacles of improving TEE utilization include the challenge of becoming familiar with the TEE machine, optimizing TEE images, and translating skills acquired in didactic or simulator center-based training into clinical use. METHODS In an effort to expand TEE utilization and improve workflow among the liver transplantation (LT) anesthesiologists at our institution, a LT-specific TEE guide was created to serve as a reference and educational tool during LT. A 26-question survey was distributed to all LT anesthesiologists before and 6 months after implementation of the LT-specific TEE guide. RESULTS All seven LT anesthesiologists completed the survey questions during the study period. No statistically significant difference was detected in participant-reported confidence in optimizing targeted TEE views, performing technical aspects of the exam, navigating the knobs on the TEE machine, or in ability to identify abnormal cardiac pathology during the study period. One participant became basic-TEE certified during the study period. CONCLUSIONS Implementing a liver transplant-specific TEE guide is a strategy to expand TEE utilization, encourage longitudinal TEE education and reinforce concepts learned from hands-on education sessions; however, we did not detect a difference in participant-reported confidence of performing a TEE exam, ability to identify abnormal cardiac pathology or altering workflow. Further studies with larger sample sizes will be needed to evaluate the effectiveness of a LT-specific TEE guide.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers
Abaza, Yasmin , Winer, Eric S. , Shallis, Rory M. , Matthews, Andrew , Badar, Talha , Geramita, Emily , Kota, Vamsi , Swaroop, Alok , Doukas, Peter H., Bradshaw, Danielle , Helenowski, Irene , Zhang, Hui , Im, Annie , Litzow, Mark R. , Perl, Alexander E. , Altman, Jessica K. , Zhang, Hui , Matthews, Andrew H , Badar, Talha , Kota, Vamsi , Swaroop, Alok , Bradshaw, Danielle , Im, Annie , Litzow, Mark R. , Perl, Alexander E , Mesulam, M-Marsel , Abaza, Yasmin , Murthy, Guru Subramanian Guru , Doukas, Peter, Liu, Yingzhe , Atallah, Ehab

Mayo Clinic

American Journal of Hematology | February 12, 2024 | Volume: 99 | Issue: 4 | Pages: 606-614

10.1002/ajh.27231 | PMID 38342997 Get It

AbstractVenetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date, real‐world data published on HMAs plus VEN have been either single‐center studies or using community‐based electronic databases with limited details on mutational landscape, tolerability, and treatment patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess the real‐world experience of 204 elderly patients (≥75 years) with newly diagnosed AML treated with HMAs plus VEN from eight academic centers in the United States. Overall, 64 patients achieved complete remission (CR; 38%) and 43 CR with incomplete count recovery (CRi; 26%) for a CR/CRi rate of 64%, with a median duration of response of 14.2 months (95% CI: 9.43, 22.1). Among responders, 63 patients relapsed (59%) with median overall survival (OS) after relapse of 3.4 months (95% CI, 2.4, 6.7). Median OS for the entire population was 9.5 months (95% CI, 7.85–13.5), with OS significantly worse among patients with TP53‐mutated AML (2.5 months) and improved in patients harboring NPM1, IDH1, and IDH2 mutations (13.5, 18.3, and 21.1 months, respectively). The 30‐day and 60‐day mortality rates were 9% and 19%, respectively. In conclusion, HMAs plus VEN yielded high response rates in elderly patients with newly diagnosed AML. The median OS was inferior to that reported in the VIALE‐A trial. Outcomes are dismal after failure of HMAs plus VEN, representing an area of urgent unmet clinical need.